Abstract
Background:YKL-40 and neurogranin are promising additional cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) which reflect different underlying disease mechanisms.Objective:To compare the levels of CSF YKL-40 and neurogranin between asymptomatic carriers of familial AD (FAD) mutations (MC) and non-carriers (NC) from the same families. Another objective was to assess changes in YKL-40 and neurogranin, from the presymptomatic to clinical phase of FAD.Methods:YKL-40 and neurogranin, as well as Aβ42, total tau-protein, and phospho-tau, were measured in the CSF of 14 individuals carrying one of three FAD mutations, APPswe (p.KM670/671NL), APParc (p.E693G), and PSEN1 (p.H163Y), as well as in 17 NC from the same families. Five of the MC developed mild cognitive impairment (MCI) during follow-up.Results:In this pilot study, there was no difference in either CSF YKL-40 or neurogranin when comparing the presymptomatic MC to the NC. YKL-40 correlated positively with expected years to symptom onset and to age in both the MC and the NC, while neurogranin had no correlation to either variable in either of the groups. A subgroup of the participants underwent more than one CSF sampling in which half of the MC developed MCI during follow-up. The longitudinal data showed an increase in YKL-40 levels in the MC as the expected symptom onset approached. Neurogranin remained stable over time in both the MC and the NC.Conclusion:These findings support a positive correlation between progression from presymptomatic to symptomatic AD and levels of CSF YKL-40, but not neurogranin.
Highlights
YKL-40, or chitinase-3-like protein, is aglycoprotein expressed by several cell types, including macrophages and vascular smooth muscle cells
In Alzheimer’s disease (AD), YKL-40 cell expression has been somewhat varied between studies and linked to both macrophages/microglia, astrocytes, and even to neurons [29,30,31]
A recent study on YKL-40 expression in human brain tissue identified a subset of astrocytes as the source of YKL-40 in AD and in tauopathies such as frontotemporal dementia [32]
Summary
S. Thordardottir et al / CSF YKL-40 and Neurogranin in Familial AD. The CSF samples were obtained in the time period between 1993 and 2015. CSF was collected into polypropylene tubes through lumbar puncture in the L3/L4 or L4/L5 interspace. The participants received premedication with 1 g paracetamol and mg diazepam prior to the procedure. After collection, the CSF was centrifuged at 3000 × g at +4◦ C for 10 min. The supernatant was pipetted off, aliquoted into polypropylene cryotubes and stored at. YKL-40 and neurogranin are promising additional cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) which reflect different underlying disease mechanisms
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
